Saturday, June 20, 2026

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,769
Drugs linked 4,797

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 102 of 1,261
  1. US 12053519

    HIV-1 Env fusion peptide nanoparticle carrier conjugates and their use

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Aug 6, 2024 · Expires Aug 1, 2044

    granted
  2. US 12053481

    Compositions and methods for deep dermal drug delivery

    ARCUTIS BIOTHERAPEUTICS, INC. · Granted Aug 6, 2024 · Expires Aug 1, 2044

    granted
  3. US 12055553

    Method for diagnosing risk for inflammatory disease through glycan profiling

    The Regents of the University of California · Granted Aug 6, 2024 · Expires Aug 1, 2044

    granted
  4. US 12054607

    Tough, healable composites displaying stress relaxation at the resin-filler interface

    The Regents of the University of Colorado, a Body Corporate · Granted Aug 6, 2024 · Expires Aug 1, 2044

    granted
  5. US 12054553

    Immunotherapeutic tumor treatment method

    Nektar Therapeutics · Granted Aug 6, 2024 · Expires Aug 1, 2044

    granted
  6. US 12054519

    Vaccine candidates for human respiratory syncytial virus (RSV) having attenuated phenotypes

    The United States of America as Represented by the Secretary, Dept. of Health and Human Services · Granted Aug 6, 2024 · Expires Aug 1, 2044

    granted
  7. US 12054533

    Anti-VEGF protein compositions and methods for producing the same

    REGENERON PHARMACEUTICALS, INC. · Granted Aug 6, 2024 · Expires Aug 1, 2044

    granted
  8. US 12054556

    Anti-PD-L1 antibody and use thereof

    Oricell Therapeutics Co., Ltd. · Granted Aug 6, 2024 · Expires Aug 1, 2044

    granted
  9. US 12054537

    Optimized nucleic acid antibody constructs encoding anti-respiratory syncytial virus (RSV) antibodies

    Inovio Pharmaceuticals, Inc. · Granted Aug 6, 2024 · Expires Aug 1, 2044

    granted
  10. US 12054501

    Compositions and methods for inhibiting arginase activity

    Precision Pharmaceuticals, Inc. · Granted Aug 6, 2024 · Expires Aug 1, 2044

    granted
  11. US 12054509

    Antimicrobial compounds, compositions, and uses thereof

    Lakewood Amedex, Inc. · Granted Aug 6, 2024 · Expires Aug 1, 2044

    granted
  12. US 12054500

    Arginase inhibitors

    Arcus Biosciences, Inc. · Granted Aug 6, 2024 · Expires Aug 1, 2044

    granted
  13. US 12054492

    Imidazole-containing inhibitors of ALK2 kinase

    BioCryst Pharmaceuticals, Inc. · Granted Aug 6, 2024 · Expires Aug 1, 2044

    granted
  14. US 12054475

    Substituted heterocycles as aldehyde dehydrogenase inhibitors

    THE TRUSTEES OF PRINCETON UNIVERSITY · Granted Aug 6, 2024 · Expires Aug 1, 2044

    granted
  15. US 12054483

    Small molecule inhibitors of DYRK/CLK and uses thereof

    Arizona Board of Regents on Behalf of the University of Arizona · Granted Aug 6, 2024 · Expires Aug 1, 2044

    granted
  16. US 12054474

    Sulfonyl piperidine derivatives and their use for treating prokineticin mediated diseases

    Takeda Pharmaceutical Company Limited · Granted Aug 6, 2024 · Expires Aug 1, 2044

    granted
  17. US 12053619

    Intradermal jet injection electroporation

    Inovio Pharmaceuticals, Inc. · Granted Aug 6, 2024 · Expires Aug 1, 2044

    granted
  18. US 12053569

    Indwelling intravascular aphaeretic system for in vivo enrichment of circulating tumor cells

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Aug 6, 2024 · Expires Aug 1, 2044

    granted
  19. US 12053520

    Glycan-masked engineered outer domains of HIV-1 gp120 and their use

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Aug 6, 2024 · Expires Aug 1, 2044

    granted
  20. US 12053526

    Methods for treatment using anti-alpha4beta7 antibody

    Takeda Pharmaceutical Company Limited · Granted Aug 6, 2024 · Expires Aug 1, 2044

    granted
  21. US 12053513

    Cancer-specific T-cell receptors

    University College Cardiff Consultants Limited · Granted Aug 6, 2024 · Expires Aug 1, 2044

    granted
  22. US 12053477

    Methods for treating pulmonary fibrosis

    REVIVA PHARMACEUTICALS, INC. · Granted Aug 6, 2024 · Expires Aug 1, 2044

    granted
  23. US 12053491

    Bispecific OR-gate chimeric antigen receptor responsive to CD19 and CD20

    The Regents of the University of California · Granted Aug 6, 2024 · Expires Aug 1, 2044

    granted
  24. US 12053494

    Compositions comprising nanoparticles, method of making and uses thereof

    ORGANICELL REGENERATIVE MEDICINE, INC. · Granted Aug 6, 2024 · Expires Aug 1, 2044

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.